Home

CARB-X is accelerating global antibacterial innovation by investing in the development of new antibiotics and other life-saving products to combat the most dangerous drug-resistant bacteria. Our projects represent the world’s largest pre-clinical and early development pipeline of antibiotics and other therapeutics, diagnostics, microbiome and vaccines. Since CARB-X was established in July 2016, it has invested $193.04 million in 57 projects around the world.

193.04

$million

Invested

57

innovative

Projects

7

different

Countries

15

focused on new classes

Pipeline

The Challenge

Accelerate the development of novel antibiotics and other new approaches to address the emergence of drug-resistant superbugs.
Learn More


Spotlight on Science

SutroVax’s new vaccine could be a game-changer in the prevention of Strep Throat infections and the spread of superbugs

Learn More

“Antibiotics transformed modern medicine but overuse and inappropriate use have led to dangerous bacteria developing deadly resistance. Drug discovery must go hand-in-hand with concerted action to ensure antibiotics of last resort are reserved for patients where first-line treatments will not work. And we must ensure these treatments are available in all countries for those who need them.”

— Tim Jinks, Head of Drug Resistant Infections, Wellcome Trust
Watch this video with Tim Jinks on what Wellcome Trust is doing to address the rise of drug-resistant bacteria.

Funders

ASPR
BARDA
WellcomeTrust
NIAID
UK Government

Alliance Partners

Bill and Melinda Gates Foundation

Accelerators and other partners

Events

Events

02.27.20

Boston, MA

Live Webinar: GARDP/REVIVE - PK/PD murine infection models: Focus on study elements, variability, and interpretation of results

03.12.20

Basel, Switzerland

BIOCOM 4th AMR Conference: Novel Antimicrobials and AMR Diagnostics

03.20.20

Cambridge, MA

BAARN2020: Boston Area Antimicrobial Research Network Meeting

CARB-X News

  • 02.18.2020  |  CARB-X funds Lytica Therapeutics to develop antibacterial peptides to treat drug-resistant infections in the lungs and other parts of the body full release

  • 02.04.2020  |  CARB-X funds Pattern Bioscience to develop a new rapid diagnostic for drug-resistant bacterial infections full release

  • 01.13.2020  |  CARB-X funds Trellis Bioscience to support the development of a monoclonal antibody designed to disrupt superbugs’ protective coating so that antibiotics can kill them full release

See All News

In The News

  • 02.05.2020  |  The Fatally Slow Quest for Next-Gen Antibiotics full story

  • 01.27.2020  |  The Broken Model of Antimicrobial Resistance: Let’s Talk About Solutions full story

  • 01.27.2020  |  Tackling antimicrobial resistance on multiple fronts full story

See All News

Sign up for CARB-X news

Get the latest news and announcements from CARB-X.